Thread by @BRAINCURES

While the GRADUATE results are not what we hoped, we are proud to have delivered a high quality and comprehensive Alzheimer’s dataset to the field, and we look forward to sharing our learnings with the community as we continue to search for new treatments-Levi Garraway CMO @Roche

https://twitter.com/Roche/status/1592055946183942145

1,965 Alzheimer's disease study participants across 30 countries were randomised 1:1 to receive gantenerumab or placebo by subcutaneous injection every 2 weeks.
Phase 3 GRADUATE I & II studies did not meet their primary endpoint of slowing clinical decline

https://twitter.com/ScienceofPD/status/1592096525127131136?s=20&t=OANZTSS-khZ_4O3o_g0_rQ

The primary endpoint for the Phase III gantenerumab study was the change from baseline on the Clinical Dementia Rating-Sum of Boxes-CDR-SB at 116 weeks. The CDR-SB measures cognitive and functional change across six areas. There were 17 secondary endpoints
roche.com/media/releases…

@alzassociation said @Roche’s results are “disappointing,” but it remains “hopeful for this class of treatment.”
“Each anti-amyloid treatment being tested acts in a different way, and research into their effectiveness and safety must continue” @DrMariaALZ
edition.cnn.com/2022/11/14/hea…

The gantenerumab setback will be an added challenge for CEO-designate Thomas Schinecker. He will replace Severin Schwan, the chief executive who has led a successful campaign to diversify away from @Roche's traditional focus on cancer @LudwigBurger $RHHBY
ibtimes.com/roches-alzheim…

“We are disappointed that the topline results from the pivotal Phase III Graduate I & II trials show that the primary endpoint of slowing clinical decline has not been met"-@muriel_vos @Roche
“These results today are disappointing" @RichJamesOakley
#EndAlz
independent.co.uk/news/health/al…

Looking ahead our commitment to researching & developing new potential treatments for Alzheimer’s disease remains steadfast. We’re in this for the long term which means decades of investing in innovation until we achieve breakthroughs-Paulo Fontoura @Roche
linkedin.com/pulse/remainin…